Clinical trials: Carcinoma, Basal Cell
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Colorectal Cancer, Triple Negative Breast Cancer, NSCLC - Adenocarcinoma
A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
The purpose of this study was to combine the PDR001 checkpoint inhibitor with each of four agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety…
- Trial name
- NCT02900664
- Testing
- PDR001, ACZ885, CJM112
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 283 people
- Sponsor
- Novartis Pharmaceuticals
Carcinoma, Basal Cell
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
The primary objective is to estimate the objective response rate (ORR) for metastatic Basal Cell Carcinoma (BCC) (group 1) and for unresectable locally advanced BCC (group 2) when treated with cemiplimab as a monotherapy
- Trial name
- NCT03132636
- Testing
- cemiplimab
- Where
- 71 sites in United States, Austria and 8 more
- Volunteers
- 138 people
- Sponsor
- Regeneron Pharmaceuticals
Basal Cell Carcinoma
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC).
- Trial name
- NCT04669808
- Testing
- STP705
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Sirnaomics
Basal Cell Carcinoma
Study to Determine the Safety of Two Applications of PEP005 Topical Gel to Nodular Basal Cell Carcinoma
The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of nodular basal cell carcinoma.
- Trial name
- NCT00108121
- Testing
- PEP005
- Where
- 10 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Peplin
Skin Neoplasms
Safety Study of a Fluorescent Marker to Visualize Cancer Cells
Many types of cancer are primarily treated with surgery and patient survival is directly related to the extent to which the tumor is able to be removed.
- Trial name
- NCT02097875
- Testing
- BLZ-100
- Where
- Australia
- Volunteers
- 21 people
- Sponsor
- Blaze Bioscience Australia Pty Ltd
Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC)
Expanded Access Use of Cemiplimab in Patients With Solid Tumors
Provide expanded access of cemiplimab in patients with solid tumors
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Basal Cell Carcinoma (BCC), Cutaneous Squamous Cell Carcinoma (CSCC)
- Trial name
- NCT06132191
- Testing
- Cemiplimab
- Sponsor
- Regeneron Pharmaceuticals
Basal Cell Carcinoma
Photodynamic Therapy (PDT) With Metvix Cream 160 mg/g Versus PDT With Placebo Cream in Participants With Primary Nodular Basal Cell Carcinoma
Photodynamic therapy (PDT) was the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulated more photosensitiser than normal cells.
- Trial name
- NCT00472108
- Testing
- Photodynamic Therapy (PDT), Metvix cream
- Where
- 9 sites in United States
- Volunteers
- 65 people
- Sponsor
- Galderma R&D
Carcinoma, Basal Cell, Carcinoma, Cutaneous Squamous Cell
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
This clinical phase II study is designed to investigate the efficacy of intratumorally administered L19IL2/L19TNF in patients with injectable lesions of BCC or cSCC.
- Trial name
- DUNCAN (NCT04362722)
- Testing
- L19IL2 +L19TNF
- Where
- 11 sites in Germany, Poland and 1 more
- Volunteers
- 40 people
- Sponsor
- Philogen S.p.A.
Non-Melanoma Skin Cancers
A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin Cancers
Open-Label study evaluating safety and efficacy of SM-020 Gel 1.0% in subjects with Seborrheic Keratoses and Non-Melanoma Skin Cancers (i.e. Basal Cell Carcinoma and Squamous Cell Carcinoma In Situ).
- Trial name
- NCT06409195
- Testing
- SM-020 1% Gel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- DermBiont, Inc.
Basal Cell Carcinoma
A Study of Vismodegib With Surgery in Participants With Previously Untreated Basal Cell Carcinoma
This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in participants with basal cell carcinoma.
- Trial name
- NCT01898598
- Testing
- Vismodegib
- Where
- 21 sites in United States
- Volunteers
- 18 people
- Sponsor
- Hoffmann-La Roche
Basal Cell Nevus Syndrome
Extension Study of Patidegib Topical Gel, 2% in Subjects With Gorlin Syndrome (Basal Cell Nevus Syndrome)
This is a multicenter, open label extension study evaluating the safety of Patidegib Topical Gel, 2%, applied topically twice daily to the face of adult subjects with Gorlin syndrome.
- Trial name
- NCT04308395
- Testing
- Patidegib Topical Gel, 2%
- Where
- 37 sites in United States, Belgium and 7 more
- Volunteers
- 108 people
- Sponsor
- Sol-Gel Technologies, Ltd.
Basal Cell Carcinoma
A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.
- Trial name
- BOLT (NCT01327053)
- Testing
- LDE225
- Where
- 62 sites in United States, Australia and 10 more
- Volunteers
- 230 people
- Sponsor
- Novartis Pharmaceuticals
Superficial Basal Cell Carcinoma
Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma
The purpose of this study is to determine the safety and tolerability of pharmaceutical compound (API 31510) topical cream topically applied to superficial basal cell carcinomas to obtain preliminary efficacy data for the…
- Trial name
- NCT00604890
- Testing
- API 31510 3% Topical Cream, API 31510 1.5% Topical Cream
- Where
- 11 sites in United States
- Volunteers
- 186 people
- Sponsor
- BPGbio
Basal Cell Carcinoma
Metvix PDT in Participant With "High Risk" Basal Cell Carcinoma
Photodynamic therapy (PDT) is the selective destruction of abnormal cells through light activation of a photosensitiser in the presence of oxygen. These cells accumulate more photosensitiser than normal cells.
- Trial name
- NCT00473343
- Testing
- Metvix® cream
- Where
- 7 sites in Australia
- Volunteers
- 102 people
- Sponsor
- Galderma R&D
Basal Cell Carcinoma
A Study to Evaluate the Effectiveness of Imiquimod 5% Cream for Basal Cell Carcinoma Recurrence
The primary objective of this study is to assess whether basal cell carcinoma (BCC) lesions surgically treated with curettage, followed by imiquimod 5% cream as postsurgical adjuvant therapy, will have an improved cure rate over…
- Trial name
- NCT00129519
- Testing
- Imiquimod 5% cream
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- Graceway Pharmaceuticals, LLC
BCC - Basal Cell Carcinoma, BCC
CellFX Treat & Resect Low-Risk BCC Feasibility Study
This prospective, multicenter, study is designed to evaluate the safety and effectiveness of the CellFX System in adults subjects with low-risk basal cell carcinoma (superficial and nodular) for complete histological clearance of…
- Conditions
- BCC - Basal Cell Carcinoma, BCC, Excision Margin
- Trial name
- NCT04918381
- Testing
- CellFX System
- Where
- 5 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Pulse Biosciences, Inc.
Solid Tumor, Adult, Solid Tumor
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
The goal of this study is determine the safety and tolerability of orally taken probiotic (R-5780) in patients currently on a PD-1 Pathway Checkpoint Inhibitor (checkpoint protein on immune cells called T cells) with Solid Tumors.
- Conditions
- Solid Tumor, Adult, Solid Tumor, Melanoma, Basal Cell Cancer
- Trial name
- NCT06398418
- Testing
- R-5780
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Rise Therapeutics LLC
Advanced Cancer, Gastric Cancer
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
This Phase I/Ib study is a Multicenter, Open-label, Dose-Escalation, Safety, Pharmacodynamic and Pharmacokinetic Study of GZ17-6.02 Monotherapy and in Combination with Capecitabine, Given Orally on a Daily Schedule in Patients…
- Conditions
- Advanced Cancer, Gastric Cancer, Breast Cancer, Pancreatic Cancer
- Trial name
- GEN602 (NCT03775525)
- Testing
- GZ17-6.02, Capecitabine
- Where
- 4 sites in United States
- Volunteers
- 127 people
- Sponsor
- Genzada Pharmaceuticals USA, Inc.
Basal Cell Carcinoma
A Study Evaluating the Efficacy and Safety of Vismodegib (GDC-0449) in Operable Basal Cell Carcinoma
This was a 3-cohort, open-label study of vismodegib (GDC-0449) in new (non-recurrent) operable basal cell carcinoma of the nodular subtype.
- Trial name
- NCT01201915
- Testing
- Vismodegib
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- Genentech, Inc.